Tag Archives: UCB

July, 2018

  • 13 July

    Amgen and UCB Resubmit BLA for Evenity to the FDA for the Treatment of Osteoporosis

    THOUSAND OAKS, Calif. and BRUSSELS, July 12, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced the resubmission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EVENITY™* (romosozumab), an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY increases bone …

July, 2017

May, 2017

April, 2017

September, 2016

February, 2016

  • 22 February

    Amgen, UCB Osteoporosis Drug Succeeds in Late-Stage Trial

    THOUSAND OAKS, Calif. and BRUSSELS, Feb. 22, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME). These data showed FRAME met the co-primary endpoints by reducing the incidence of new vertebral fracture through …